Summary by Futu AI
Hepalink Pharmaceutical Holdings Limited (Hepalink Pharmaceutical-B) submitted the next day disclosure report on September 24, 2024, disclosing its shareholding changes. According to the report, on September 24, 2024, the company repurchased 300,000 common shares at a repurchase price ranging from HKD 1.21 to HKD 1.26 per share, with a total payment of HKD 372,780. The repurchased shares will be held as treasury shares. After the repurchase, the company's issued shares decreased from 767,922,410 shares to 767,622,410 shares, while the treasury shares increased from 954,000 shares to 1,254,000 shares. The company confirmed that this share repurchase has been formally authorized and approved by the board of directors, and complies with all applicable listing rules, laws, and other regulatory requirements. In addition, the repurchase authorization obtained by the company on June 6, 2024, allows it to repurchase up to 76,887,641 shares. Currently, 1,254,000 shares have been repurchased, accounting for 0.163% of the shares issued on that day. After the repurchase activities, the company will enter a moratorium period on new share issuance or further sale or transfer of treasury shares until October 24, 2024."
